Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study
Objective: Improvement of on-off symptoms in ambulatory patients with Parkinson's disease (PD) by introduction of a multi-faceted medication optimization program. This consisted of a patient…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey
Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…Upper limb motor tests are related to clinical ratings of motor function in advanced Parkinson’s disease
Objective: The aim of this study was to investigate whether upper limb motor tests are related to clinical ratings of motor function in Parkinson's disease…Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I
Objective: Evaluate the safety of opicapone (OPC) in Parkinson's disease patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background: OPC,…Therapeutic yoga improves balance and balance confidence in Parkinson’s disease
Objective: The objective of this study was to improve balance and balance confidence in individuals with Parkinson's disease (PD) following an 8-week therapeutic yoga intervention.…Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias
Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review. Background: Repurposing drugs that have already been proven…Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up
Objective: To follow the clinical status of 4 PD patients transplanted with NTCELL out to 81-130 weeks. Background: NTCELL comprises neonatal porcine choroid plexus cells…Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies
Objective: Evaluate the proportion of patients with Parkinson's disease and motor fluctuations responding to opicapone (OPC) or placebo treatment over a 14-15 week treatment period.…Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies
Objective: Evaluate the onset and stability of the therapeutic effect of opicapone (OPC) compared to placebo in patients with Parkinson's disease and motor fluctuations over…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.